Probing the molecular interactions within carrier nanopores to enable model validation and deployment

探测载体纳米孔内的分子相互作用以实现模型验证和部署

• 批准号: 10061626
• 金额: $ 3.11万
• 依托单位: MESOX LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10061626
• 关键词: Probing; molecular; interactions; within; carrier

MESOX developed a novel particle carrier technology for enhancing the bioavailability of medicines. The carrier has nanopores within its structure and each nanopore behaves like a nano-container for drug molecules. When a drug is loaded within a nanopore, it converts to its amorphous solid form which easily dissolves in the patient body. As a result, drug efficacy could be enhanced due to better absorption, and lower doses would be required as opposed to the drug in its native state without our carrier.In line with the developed carrier, we have also built a molecular model of the carrier which allows us to screen drugs virtually on a computer prior to conducting laboratory experiments. This provides two key advantages to potential pharma and biotech customers:1- Saves their precious drug through avoiding extensive experimental formulation work.2- Provides quick feedback on the feasibility of our carrier technology for their drug molecule.However, a key to unlocking the power of this molecular model is to validate its observations using an advanced analytical technique. A technique is needed that can quantify the amount of drug within carrier (maximum amount that can be loaded), nature of drug loaded within carrier (molecular interactions, amorphous/crystalline phase) and preserves the carrier structure during the analysis process (for reliable results).The national physical laboratory will assist us with an advanced analytical technique that meets the above criteria for model validation.Our modelling capability once validated will represent a leap forward in formulation development science. It will help reduce the risks of the formulation process leading to lower product costs, and accelerate the timelines for the development of new medicines.Ultimately, this approach could lead to more lifesaving medicines getting into patients' hands quicker and saving the NHS and the UK taxpayer millions of pounds in healthcare costs.

MESOX 开发了一种新型颗粒载体技术，用于提高药物的生物利用度。该载体的结构内具有纳米孔，每个纳米孔的行为就像药物分子的纳米容器。当药物装载到纳米孔内时，它会转化为无定形固体形式，很容易溶解在患者体内。因此，与没有载体的药物在天然状态下相比，由于更好的吸收而可以增强药物功效，并且需要更低的剂量。根据开发的载体，我们还建立了载体的分子模型，使我们能够在进行实验室实验之前在计算机上虚拟筛选药物。这为潜在的制药和生物技术客户提供了两个关键优势：1- 通过避免大量的实验配制工作来节省宝贵的药物。2- 提供有关我们的载体技术对其药物分子的可行性的快速反馈。然而，释放该分子模型力量的关键是使用先进的分析技术验证其观察结果。需要一种能够量化载体内药物量（可装载的最大量）、载体内装载药物的性质（分子相互作用、非晶/晶相）并在分析过程中保留载体结构（以获得可靠结果）的技术。国家物理实验室将协助我们提供符合上述模型验证标准的先进分析技术。我们的建模能力一旦得到验证，将代表制剂开发科学的飞跃。它将有助于降低配方过程的风险，从而降低产品成本，并加快新药开发的进度。最终，这种方法可以使更多救生药物更快地到达患者手中，并为 NHS 和英国纳税人节省数百万英镑的医疗费用。